ALLO
Allogene Therapeutics, Inc.
Overview
Allogene Therapeutics develops genetically engineered allogeneic CAR T cell therapies—off-the-shelf cancer and autoimmune disease treatments derived from healthy donors rather than individual patients.
Allogene Therapeutics, Inc is a Healthcare company operating in Biotechnology with a $724.8M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 11, 2026).
20 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-1412 Q&A exchanges
- Q4 FY2025Earnings2026-03-127 Q&A exchanges
- Q3 FY2025Earnings2025-11-0714 Q&A exchanges
- Q2 FY2025Earnings2025-08-1321 Q&A exchanges
- Q1 FY2025Earnings2025-05-1326 Q&A exchanges
- Q4 FY2024Earnings2025-03-1324 Q&A exchanges
- Q3 FY2024Earnings2024-11-0713 Q&A exchanges
- Q1 FY2024Earnings2024-05-1316 Q&A exchanges
- Q4 FY2023Earnings2024-03-1416 Q&A exchanges
- Q3 FY2023Earnings2023-11-0214 Q&A exchanges
- Q2 FY2023Earnings2023-08-0219 Q&A exchanges
- Q1 FY2023Earnings2023-05-0318 Q&A exchanges
- Q4 FY2022Earnings2023-02-2817 Q&A exchanges
- Q3 FY2022Earnings2022-11-0219 Q&A exchanges
- Q2 FY2022Earnings2022-08-0915 Q&A exchanges
- Q1 FY2022Earnings2022-05-0412 Q&A exchanges
- Q4 FY2021Earnings2022-02-2319 Q&A exchanges
- Q3 FY2021Earnings2021-11-0435 Q&A exchanges
- Q2 FY2021Earnings2021-08-0415 Q&A exchanges
- Q1 FY2021Earnings2021-05-0529 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-11EPS— vs $-0.16—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-11 | — | $-0.16 | — | — | — | — | EODHD |
Source: EODHD. ALLO reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks ALLO's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 50% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $0.90 | $0.65 | +37.8% | 0.0% | -1.1% |
| Q4 FY2026 | $0.99 | $0.74 | +33.5% | -0.8% | +1.9% |
| Q3 FY2026 | $0.83 | $0.63 | +31.3% | -1.2% | -1.5% |
| Q2 FY2026 | $1.04 | $0.82 | +27.2% | +7.7% | +5.5% |
| Q1 FY2025 | $0.86 | $0.64 | +33.6% | +8.1% | +5.7% |
| Q4 FY2025 | $1.13 | $0.82 | +37.2% | +3.5% | +4.3% |
| Q3 FY2025 | $0.90 | $0.65 | +38.1% | +3.4% | +3.1% |
| Q2 FY2025 | $1.12 | $0.87 | +29.0% | -1.3% | -0.6% |
| Q1 FY2024 | $1.23 | $0.91 | +34.8% | +3.8% | +2.8% |
| Q4 FY2024 | $1.06 | $0.84 | +26.5% | -2.4% | -3.2% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- David D ChangCEO1 yr 4 mo19 callsCurrentSample
CEO since 2025 • 1/4 beats (25%) • guidance suspended Q1 FY2026
- Geoffrey M ParkerCFO1 yr 5 mo4 callsCurrentSample
CFO since 2025 • 1/4 beats (25%) • guidance suspended Q1 FY2026
- Benjamin MacHinas BeneskiSVP, Chief Technical Officer1 yr 3 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 2/4 beats (50%) • last guidance raise Q1 FY2026
- Earl Martin DouglasSVP, General Counsel1 yr 5 mono recorded callsCurrentSample
DIVISION_HEAD since 2025 • 2/4 beats (50%) • last guidance cut Q2 FY2026
- Zachary RobertsEVP of R&D1 yr 5 mo12 callsCurrentSample
DIVISION_HEAD since 2025 • 2/4 beats (50%) • guidance suspended Q2 FY2026
- Annie YoshiyamaSVP, Finance1 yr 5 mono recorded callsCurrentSample
DIVISION_HEAD since 2025 • 2/4 beats (50%) • last call held guidance Q3 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ALLO.
$ curl https://api.spokenalpha.com/v1/companies/ALLOFAQ
Frequently asked about ALLO
Where can I find Allogene Therapeutics, Inc.'s (ALLO) earnings call transcripts?
Spoken Alpha indexes ALLO's earnings call transcripts at https://spokenalpha.com/companies/ALLO. Each call links to attributed speakers and parsed analyst Q&A. Allogene Therapeutics, Inc.'s own investor relations page is at https://ir.allogene.com/.
When was Allogene Therapeutics, Inc.'s most recent earnings call?
Allogene Therapeutics, Inc. (ALLO) held its most recent earnings call on 2026-05-14, covering fiscal Q1 2026.
What sector is ALLO in?
Allogene Therapeutics, Inc. (ALLO) operates in the Healthcare sector (Biotechnology industry).